Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.

Saad A, Taneja A, Di Stasi A, Sarmad R, Kukkamalla R, Costa L, Salzman D, Innis-Shelton R, Chewning JH, Meredith RF, Hauptfeld V, Langford S, Plessala K, Bhatia R, Lamb LS, Mineishi S.

Bone Marrow Transplant. 2018 Oct;53(10):1345-1348. doi: 10.1038/s41409-018-0185-6. Epub 2018 May 4. No abstract available.

PMID:
29728698
2.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2018 Jul;41(7):716-721. doi: 10.1097/COC.0000000000000353.

3.

A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.

Fiveash JB, Arafat WO, Naoum GE, Guthrie BL, Sawrie SM, Spencer SA, Meredith RF, Markert JM, Conry RM, Nabors BL.

Adv Radiat Oncol. 2016 Apr 1;1(2):83-88. doi: 10.1016/j.adro.2016.03.004. eCollection 2016 Apr-Jun.

4.

MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K; SNMMI MIRD Committee, Bolch WE, Brill AB, Fahey F, Fisher DR, Hobbs R, Howell RW, Meredith RF, Sgouros G, Zanzonico P; EANM Dosimetry Committee, Bacher K, Chiesa C, Flux G, Lassmann M, Strigari L, Walrand S.

J Nucl Med. 2016 Jan;57(1):151-62. doi: 10.2967/jnumed.115.159012. Epub 2015 Oct 15.

5.

Pazopanib combined with radiation: in vivo model of interaction.

Meredith RF, Raisch KP, Bonner JA, Buchsbaum DJ, Grizzle WE, Li Y, Spencer SA.

Cancer Biother Radiopharm. 2014 Aug;29(6):247-50. doi: 10.1089/cbr.2013.1583. Epub 2014 Jun 19.

PMID:
24945464
6.

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R.

Cancer Biother Radiopharm. 2014 Feb;29(1):12-7. doi: 10.1089/cbr.2013.1531. Epub 2013 Nov 14.

7.

MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.

Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC; SNMMI MIRD Committee, Bolch WE, Brill AB, Dunphy M, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW.

J Nucl Med. 2013 Dec;54(12):2182-8. doi: 10.2967/jnumed.113.122390. Epub 2013 Oct 15.

8.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A.

Cancer Biother Radiopharm. 2013 Jun;28(5):370-9. doi: 10.1089/cbr.2012.1387. Epub 2013 Mar 26.

PMID:
23530878
9.

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Shen S, Forero A, Meredith RF, LoBuglio AF.

Cancer Biother Radiopharm. 2011 Feb;26(1):127-33. doi: 10.1089/cbr.2010.0864.

PMID:
21355784
10.

Renal dosimetry.

Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros G, Thomas SR.

Cancer Biother Radiopharm. 2010 Oct;25(5):597-9. doi: 10.1089/cbr.2010.0867. Epub 2010 Sep 28. No abstract available.

PMID:
20874486
11.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

12.

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G; SNM MIRD Committee, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB.

J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15.

13.

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF.

J Nucl Med. 2010 Jan;51(1):150-7. doi: 10.2967/jnumed.109.066597. Epub 2009 Dec 15.

14.

Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.

Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D.

J Pain Symptom Manage. 2009 Oct;38(4):522-32. doi: 10.1016/j.jpainsymman.2008.12.004. Epub 2009 Jul 15.

15.

Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.

Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):403-9. doi: 10.1016/j.ijrobp.2009.02.017. Epub 2009 May 19.

PMID:
19467801
16.

Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer.

Caudell JJ, Meredith RF, Spencer SA, Keene KS, Dobelbower MC, Bonner JA.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):164-8. doi: 10.1016/j.ijrobp.2009.01.037.

PMID:
19386438
17.

MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.

Fisher DR, Shen S, Meredith RF.

J Nucl Med. 2009 Apr;50(4):644-52. doi: 10.2967/jnumed.108.057331. Epub 2009 Mar 16. Erratum in: J Nucl Med. 2012 Apr;53(4):646.

18.

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR.

J Nucl Med. 2008 Nov;49(11):1884-99. doi: 10.2967/jnumed.108.053173. Epub 2008 Oct 16. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

19.

Targeted radionuclide therapy.

Williams LE, DeNardo GL, Meredith RF.

Med Phys. 2008 Jul;35(7):3062-8.

20.

Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5. doi: 10.1016/j.ijrobp.2008.04.048. Epub 2008 Jul 16.

PMID:
18635320

Supplemental Content

Loading ...
Support Center